|
|
|
Molecular Detection Inc. (MDI) is developing and commercializing a portfolio of "sample-to-answer" Detect-Ready™ molecular diagnostic tests for the rapid detection of infectious diseases. The company recently launched its first product, the Detect-Ready™ MRSA assay, in Germany and the U.K, and several other countries in Europe. The Detect-Ready™ MRSA assay allows for the rapid detection of methicillin-resistant Staphylococcus aureus (MRSA), a growing problem among hospitals and other health facilities around the globe.
MDI’s mission is to become a leading molecular diagnostics company leveraging its novel technologies to commercialize products for the accurate, rapid and cost-effective detection of infectious diseases. MDI's Detect-Ready MRSA assay is a real-time PCR test designed to provide increased accuracy, faster time to results and more efficient utilization of hospital resources than other MRSA diagnostic products. MDI is also developing Detect-Ready assays to test for the presence of other microbial agents, including C.difficile, sexually transmitted diseases (STDs) and foodborne pathogens. The company’s products are based on novel patent-pending technologies that provide greater accuracy and speed while simplifying assay storage and use.
MDI was founded in 2007 and is headquartered in Wayne, PA. It has research operations and an ISO 9001 and 13485 certified manufacturing facility in Israel.
|
|
|
|
|
